BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will present an oral abstract and poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 – June 4, 2024 in Chica...
Cue Biopharma, Inc. (NASDAQ:CUE ) Q4 2023 Earnings Conference Call April 8, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Stephen Willey - Stifel Ren Benjamin - JMP Operator Greetings and welcome to the Cue Biopharma Investor Update call. At ...
BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexa...
BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit being held virtually from December 5-6, 2023.
Cue Biopharma, Inc. (NASDAQ:CUE ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Daniel Passeri - CEO Matteo Levisetti - Chief Medical Officer Anish Suri - President & Chief Scientific Officer Kerri-Ann Millar - CFO Conference Call Participants Reni Benjamin - JMP Securities Ted Tenthoff - Piper Sandler Operator Good afternoon, ladies and gentlemen, and welcom...
BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this November, the Stifel Healthcare Conference, to be held in New York from November 14-15, the Jefferies London ...
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today the presentation of new positive data from its ongoing fully enrolled Phase 1 trials evaluating its lead interleukin-2 (IL-2)-based T cell engager, CUE-101, as a monothe...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.